Duane B. Welling, Ph.D.
Affiliations: | 2003 | Ohio State University, Columbus, Columbus, OH |
Area:
Molecular BiologyGoogle:
"Duane Welling"Parents
Sign in to add mentor| Long-Sheng Chang | grad student | 2003 | Ohio State | |
| (Vestibular schwannoma: Dissecting the pathogenic process and clinical applications.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Allaway R, Angus SP, et al. (2018) Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. Plos One. 13: e0197350 |
| Oblinger JL, Burns SS, Akhmametyeva EM, et al. (2016) Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology |
| Chow HY, Dong B, Duron SG, et al. (2015) Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 6: 1981-94 |
| Petrilli A, Copik A, Posadas M, et al. (2014) LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 33: 3571-82 |
| Spear SA, Burns SS, Oblinger JL, et al. (2013) Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 34: 1519-27 |
| Burns SS, Akhmametyeva EM, Oblinger JL, et al. (2013) Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Research. 73: 792-803 |
| Bush ML, Burns SS, Oblinger J, et al. (2012) Treatment of vestibular schwannoma cells with ErbB inhibitors. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 33: 244-57 |
| Jacob A, Oblinger J, Bush ML, et al. (2012) Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122: 174-89 |
| Bush ML, Oblinger J, Brendel V, et al. (2011) AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13: 983-99 |
| Lee TX, Packer MD, Huang J, et al. (2009) Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer (Oxford, England : 1990). 45: 1709-20 |